Intraperitoneal delivery of nanoparticles for cancer gene therapy

Future Oncology

Volumn 9, Issue 1, 2013, Pages 59-68

  Hallaj Nezhadi, Somayeh ^a   Dass, Crispin R ^b   Lotfipour, Farzaneh ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b VICTORIA UNIVERSITY   (Australia)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cancer; gene delivery; gene therapy; intraperitoneal; nanoparticle; plasmid

Indexed keywords

CHOLESTEROL; CISPLATIN; CLAUDIN 3; CYCLODEXTRIN; FILAMIN A INTERACTING PROTEIN 1 LIKE; GANCICLOVIR; HEPARIN; INTERLEUKIN 12; MACROGOL; NANOPARTICLE; PACLITAXEL; PHOSPHATIDYLCHOLINE; POLYETHYLENEIMINE; POLYGLACTIN; PROTAMINE SULFATE; RAD51 PROTEIN; SILICON DIOXIDE; SMALL INTERFERING RNA; THYMIDINE KINASE; TRANSFERRIN; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS MATRIX PROTEIN; VIRUS PROTEIN;

ABDOMINAL CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CONNECTIVE TISSUE; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; GENE DELIVERY SYSTEM; HUMAN; LOCAL THERAPY; METASTASIS; NONHUMAN; OVARY CANCER; OVARY TUMOR; PERITONEAL CAVITY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMACH CANCER; SUICIDE GENE; SUICIDE GENE THERAPY; TARGET CELL;

DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; INJECTIONS, INTRAPERITONEAL; NANOPARTICLES; NEOPLASMS;

EID: 84871462413     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.171     Document Type: Review

References (35)

1. Habib NA. Cancer Gene Therapy Past Achievements and Future Challenges. Kluwer Academic Publishers, NY, USA, 5-7 (2000).
2. Hallaj-Nezhadi S, Choong PFM, Lotfipour F, Dass CR. Gelatin-based delivery systems for cancer gene therapy. J. Drug Target 17(10), 731-738 (2009).
3. Schmidt-Wolf GD, Schmidt-Wolf IG. Non-viral and hybrid vectors in human gene therapy: An update. Trends Mol. Med. 9(2), 67-72 (2003). (Pubitemid 36313867)
4. Davis ME. Non-viral gene delivery systems. Curr. Opin. Biotechnol. 13(2), 128-131 (2002). (Pubitemid 34310371)
5. Hallaj-Nezhadi S, Lotfipour F, Dass C. Nanoparticle-mediated interleukin-12 cancer gene therapy. J. Pharm. Pharm. Sci. 13(3), 472-485 (2010).
6. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54(5), 631-651 (2002). (Pubitemid 35247520)
7. Hallaj-Nezhadi S, Lotfipour F, Dass CR. Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy. Pharmazie 65(12), 855-859 (2010).
8. Hallaj-Nezhadi S, Valizadeh H, Dastmalchi S et al. Preparation of chitosan-plasmid DNA nanoparticles encoding interleukin-12 and their expression in CT-26 colon carcinoma cells. J. Pharm. Pharm. Sci. 14(2), 181-195 (2011).
9. Basarkar A, Singh J. Nanoparticulate systems for polynucleotide delivery. Int. J. Nanomed. 2(3), 353-360 (2007). (Pubitemid 350047779)
10. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed. Pharmacother. 58(3), 168-172 (2004). (Pubitemid 38479921)
11. Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after intravenous injection in mice: Involvement of scavenger receptors in its hepatic uptake. Pharm. Res. 12(6), 825-830 (1995).
12. Dass CR, Saravolac EG, Li Y, Sun LQ. Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev. 12(5), 289-299 (2002). (Pubitemid 35375494)
13. Kass-Eisler A, Falck-Pedersen E, Elfenbein DH, Alvira M, Buttrick PM, Leinwand LA. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1(6), 395-402 (1994).
14. Chanda N, Kattumuri V, Shukla R et al. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc. Natl Acad. Sci. USA 107(19), 8760-8765 (2010).
15. Flessner MF. The transport barrier in intraperitoneal therapy. Am. J. Physiol. Renal. Physiol. 288(3), F433-F442 (2005). (Pubitemid 40279447)
16. Intra J, Salem AK. Characterization of the transgene expression generated by branched and linear polyethylenimineYplasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo. J. Control. Rel. 130(2), 129-138 (2008).
17. Flessner MF. Endothelial glycocalyx and the peritoneal barrier. Peritoneal Dial. Int. 28(1), 6-12 (2008). (Pubitemid 351566118)
18. Flessner MF. Peritoneal transport physiology: Insights from basic research. JASN 2(2), 122-135 (1991).
19. Bajaj G, Yeo Y. Drug delivery systems for intraperitoneal therapy. Pharm. Res. 27(5), 735-738 (2010).
20. Lu Z, Wang J, Wientjes MG, Au JL. Intraperitoneal therapy for peritoneal cancer. Future Oncol. 6(10), 1625-1641 (1625).
21. Pun SH, Tack F, Bellocq NC et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol. Ther. 3(7), 641-650 (2004). (Pubitemid 41351103)
22. Tan K, Cheang P, Ho IA, Lam PY, Hui KM. Nanosized bioceramic particles could function as efficient gene delivery vehicles with target specificity for the spleen. Gene Ther. 14(10), 828-835 (2007). (Pubitemid 46706061)
23. Sawicki JA, Anderson DG, Langer R. Nanoparticle delivery of suicide DNA for epithelial ovarian cancer therapy. Adv. Exp. Med. Biol. 622, 209-219 (2008).
24. Huang YH, Zugates GT, Peng W et al. Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice. Cancer Res. 69(15), 6184-6191 (2009).
25. Hine CM, Seluanov A, Gorbunova V. Use of the Rad51 promoter for targeted anti-cancer therapy. Proc. Natl Acad. Sci. USA 105(52), 20810-20815 (2008).
26. Hine CM, Seluanov A, Gorbunova V. Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer. Mol. Ther. 20(2), 347-355 (2012).
27. Fewell JG, Matar MM, Rice JS et al. Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. J. Gene Med. 11(8), 718-728 (2009).
28. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res. 11(19 Pt 1), 6966-6971 (2005). (Pubitemid 41428755)
29. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 153(4), 1249-1256 (1998). (Pubitemid 28465848)
30. Gou M, Men K, Zhang J et al. Efficient inhibition of C-26 colon carcinoma by VSVMP gene delivered by biodegradable cationic nanogel derived from polyethyleneimine. ACS Nano 4(10), 5573-5584 (2011).
31. Xie C, Gou ML, Yi T et al. Efficient inhibition of ovarian cancer by truncation mutant of FILIP1L gene delivered by novel biodegradable cationic heparinY polyethyleneimine nanogels. Hum. Gene Ther. 22(11), 1413-1422 (2011).
32. Sun C, Yi T, Song X et al. Efficient inhibition of ovarian cancer by short hairpin RNA targeting claudin-3. Oncol. Rep. 26(1), 193-200 (2011).
33. Swarbrick J. Encyclopedia of Pharmaceutical Technology (3rd Edition).Informa Healthcare USA Inc., NY, USA (2007).
34. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12(5), 461-466 (2005). (Pubitemid 40394299)
35. Kajiwara E, Kawano K, Hattori Y, Fukushima M, Hayashi K, Maitani Y. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy. J. Control. Rel. 120(1-2), 104-110 (2007). (Pubitemid 46874624)